12:00 AM
 | 
Dec 16, 2002
 |  BioCentury  |  Product Development

Boosting Rituxan

Despite a clinical failure with IDEC-114 in psoriasis this year, Idec Pharmaceuticals Corp. has not given up on the antibody, which targets the CD80 antigen on B cells. Data presented at the American Society of Hematology meeting in Philadelphia last week suggest the molecule has activity against non-Hodgkin's lymphoma. In fact, IDPH hopes to use IDEC-114 in combination with its marketed Rituxan rituximab antibody, which targets CD20, to lengthen the duration of response to Rituxan among refractory NHL patients.

In the ongoing Phase I/II study reported at ASH, three of 16 patients given the high...

Read the full 474 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >